Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/ledipasvir for hospitalized COVID-19
IRCT20100228003449N29Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sofosbuvir and ledipasvir in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Treatment response rate and Adverse drug reactions. Started Mar 2020; status: completed.
02
Drugs
sofosbuvirledipasvir
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20100228003449N29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100228003449N29.